{"acquisitions":[],"changes":[],"country":"US","description":"Nuvig Therapeutics is a Menlo Park clinical-stage biotech developing engineered Fc fragments that mimic sialylated IgG to treat autoimmune disease. It targets CIDP patients dependent on costly IVIG infusions. Lead drug NVG-2089 binds type-II Fc receptors to match IVIG effects at far lower doses; now in Phase 2.","domain":"nuvig.com","employees":null,"founded":null,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":37.451967,"lng":-122.177992,"location":"Menlo Park CA","multiples":[],"name":"Nuvig Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":161000000,"connectionsAmong":[],"currency":"USD","date":"2024-12-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"nuvig-com-2024-12-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"nuvig-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-07","status":"attributed","url":null},{"fact":"existence","publisher":"nuvig.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://nuvig.com"},{"fact":"description","publisher":"nuvig.com","retrievedAt":"2026-05-07","status":"self-reported","url":"https://nuvig.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":["Nginx"],"totalRaisedUsd":161000000,"traction":[],"updatedAt":"2026-05-07","valuations":[]}